Abstract:ID 87764 Poster Board 443 Small molecule activators of the mitochondrial matrix protease, caseinolytic protease proteolytic subunit (ClpP), are under investigation for the treatment of aggressive and resilient cancers. Exemplified by the imipridones (ONC201/206, Chimerix), these and related analogs (TR compounds, Madera Therapeutics), disrupt multiple mitochondrial processes required for cancer cell growth. These ClpP agonists induce ClpP-dependent degradation of select matrix proteins, interrupting TCA cycle function, OXPHOS and mitochondrial metabolism, culminating in cancer cell senescence. Our investigation demonstrated that ClpP agonists also cause the degradation of select protein components of the mitochondrial import machinery known as the presequence translocase-associated motor (PAM) complex. Further experimentation demonstrated a concomitant cytosolic accumulation of the senescence-associated mitochondrial matrix protein GRSF1, indicating impairment of import. The goal of this study was to investigate how ClpP activation affects PAM complex proteins and how disruption of this translocase process impacts mitochondrial protein import and function. ClpP-dependent changes in mitochondrial protein abundance were investigated by immunoblotting. Subcellular localization of proteins was determined by manual fractionation of samples into mitochondrial and cytosolic fractions. Log fold changes in PAM complex protein levels were also determined via a global proteomics screen and quantitative peptide analysis using mass spectrometry. All experiments were done in wildtype, triple-negative breast cancer cells (TNBC cells: SUM159, MDA-MB-231) or their corresponding ClpP-knockout derivatives. Following ClpP-agonist treatment of TNBC cells, we detected a ~15 kDa increase in the molecular weight (MW) of the senescence-associated protein GRSF1 by immunoblot. This increase in MW was consistent with retention of the mitochondrial transit sequence (MTS), which is normally cleaved following import into the mitochondrial matrix. Subcellular fractionation revealed accumulation of the higher-weight GRSF1 (65 kDa) in the cytosolic fraction and a depletion of the lower-weight GRSF1 (50 kDa) from the mitochondrial fraction. Parallel proteomics data revealed a ClpP-agonist-dependent decrease in several PAM complex proteins (GRPEL1/2, TIMM44). The decline in GRPEL1 was validated by immunoblot analysis. Finally, the knockdown of specific PAM complex proteins was examined to confirm the effects of PAM complex protein loss on GRSF1 mitochondrial import. Our proteomics data that demonstrated a ClpP-dependent decrease in PAM complex proteins, suggested that mitochondrial protein import would be impaired. Following the fate of GRSF1, we confirmed this hypothesis and highlighted the importance of specific PAM complex proteins in this process. Similar MW shifts were observed with other mitochondrial matrix proteins (ALAS1, GPT2), suggesting broad effects of ClpP agonists on mitochondrial protein import. Previous studies showed that knockdown and inhibition of GRSF1's mitochondrial function was linked to increased senescence. Our data demonstrating ClpP-dependent inhibition of mitochondrial import suggests that this may be another mechanism by which ClpP agonists disrupt GRSF1 function and facilitate the development of senescence in TNBC. NIH GM ROI 138520 Drug-induced ClpP activation leads to PAM complex and mitochondrial matrix GRSF1 degradation

Abstract A014: ClpP drives efficacy and mediates acquired resistance with imipridones ONC201 and ONC206 in glioma in vitro

Exth-37. Allosteric Mitochondrial Clpp Agonist Onc206 Alters Stress Response, Metabolic And Epigenetic Profiles To Elicit Anti-Cancer Efficacy In High-Grade Gliomas

Abstract 3173: Impact of hypoxia on the integrated stress response activated by imipridones ONC201 and ONC206 in pediatric diffuse midline glioma cells

Abstract 4604: Imipridones ONC201 and ONC212 exhibit anti-tumor activity in biliary tract cancers and synergy when combined with trametinib and olaparib in vitro

Tmet-16. Gaba Production Induced By Imipridones Is A Targetable And Imageable Metabolic Alteration In Diffuse Midline Gliomas

GABA production induced by imipridones is a targetable and imageable metabolic alteration in diffuse midline gliomas

Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Abstract 5841: A genome wide CRISPR-Cas9 screen identifies mediators of resistance to dual PI3K/mTOR inhibition in glioblastoma multiforme

Abstract 2671: Imipridones ONC201 and ONC206 reduce expression of neogenin and EZH1/2 which correlate with synergy following their combination with EZH1/2 or HDAC inhibitors in treatment of DMG and other tumors

Abstract 5470: ONC206 inhibits tumour growth and is a potential novel therapeutic strategy for refractory medulloblastoma

Abstract 5321: Novel imipridone ONC206 inhibits cell proliferation and induces apoptosis in uterine serous cancer through altering MAPK/AKT signaling network and metabolic reprogramming

Abstract 2078: The imipridone ONC212 cooperates with MEK and immune checkpoint inhibition to elicit in vivo regression of KPC mouse pancreatic tumors

Abstract 7596: (TTFields) and imipridone ONC206 co-treatment inhibits p-AKT and spheroid growth and upregulates caspase-10 in human GBM cell lines

Abstract 4898: Imipridones and EZH2 inhibitors induce similar changes in cytokines and regulated genes in GBM and DMG while vorinostat potentiates anti-tumor efficacy despite variability in cytokine profiles

Abstract 3331: Preclinical combination of ONC206 with radiotherapy and temozolomide in a GBM mouse orthotopic model

Abstract 7228: In-vitro efficacy of Dordaviprone/GSK126 combination therapy on castration resistant and neuroendocrine prostate cancer

Small Molecule ClpP-Agonists Block Mitochondrial GRSF1 Entry by Degrading Import Machinery

Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors

Abstract 524: Using acquired resistance to explore the mechanism of action of the integrated stress response/GCN2 activator NXP800 - A new developmental agent for platinum-resistant ARID1A mutant ovarian cancer

Abstract 541: Establishment of Inotuzumab ozogamicin resistant leukemia cell lines; Focusing on p-gp and DNA damage repair for overcoming drug resistance